MX2009003726A - R-espondinas como moduladores de la angiogenesis y vasculogenesis. - Google Patents

R-espondinas como moduladores de la angiogenesis y vasculogenesis.

Info

Publication number
MX2009003726A
MX2009003726A MX2009003726A MX2009003726A MX2009003726A MX 2009003726 A MX2009003726 A MX 2009003726A MX 2009003726 A MX2009003726 A MX 2009003726A MX 2009003726 A MX2009003726 A MX 2009003726A MX 2009003726 A MX2009003726 A MX 2009003726A
Authority
MX
Mexico
Prior art keywords
rspo2
angiogenesis
rspo3
rspondins
vasculogenesis
Prior art date
Application number
MX2009003726A
Other languages
English (en)
Inventor
Christof Niehrs
Olga Kazanskaya
Bisei Okawara
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39149425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of MX2009003726A publication Critical patent/MX2009003726A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere al uso de las R-espondinas, particularmente la R-espondina2 (Rspo2) o R-espondina3 (Rspo3) o ácido nucleico de la R-espondina, o reguladores o efectores o moduladores de la R-espondina por ejemplo, el Rspo2 y/o Rspo3 para promover o inhibir la angiogénesis y/o vasculogénesis, respectivamente. La invención se basa en la demostración de que el Rspo3 y Rspo2 son promotores de la angiogénesis y la identificación del Rspo2 y 3 como los reguladores positivos del factor de crecimiento endotelial vascular (VEGF). Estos resultados indican un mejor papel para las R-espondinas, particularmente el Rspo3 y/o Rspo2 en el sistema de señalización durante la angiogénesis. La invención también se refiere al uso de los reguladores o efectores o moduladores de la R-espondina3, incluyendo los agonistas y antagonistas, en el tratamiento de las condiciones donde el tratamiento involucra inhibir o promover la angiogénesis y/o vasculogénesis.
MX2009003726A 2006-10-20 2007-10-19 R-espondinas como moduladores de la angiogenesis y vasculogenesis. MX2009003726A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06022070 2006-10-20
PCT/EP2007/009105 WO2008046649A1 (en) 2006-10-20 2007-10-19 Rspondins as modulators of angiogenesis and vasculogenesis

Publications (1)

Publication Number Publication Date
MX2009003726A true MX2009003726A (es) 2009-04-22

Family

ID=39149425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003726A MX2009003726A (es) 2006-10-20 2007-10-19 R-espondinas como moduladores de la angiogenesis y vasculogenesis.

Country Status (13)

Country Link
US (6) US8088374B2 (es)
EP (2) EP2997975A1 (es)
JP (2) JP5777281B2 (es)
AU (1) AU2007312538B2 (es)
CA (1) CA2664828A1 (es)
DK (1) DK2081586T4 (es)
ES (1) ES2564794T5 (es)
HK (1) HK1222799A1 (es)
HU (1) HUE027179T2 (es)
MX (1) MX2009003726A (es)
PL (1) PL2081586T5 (es)
SI (1) SI2081586T2 (es)
WO (1) WO2008046649A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
CA2664828A1 (en) † 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP3441458B9 (en) 2009-02-03 2023-08-23 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2419133A1 (en) * 2009-04-15 2012-02-22 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
ES2573643T3 (es) * 2009-12-23 2016-06-09 Deutsches Krebsforschungszentrum Receptores de Rspo2 y Rspo3
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
AU2012351977B2 (en) * 2011-12-14 2018-03-22 The Board Of Trustees Of The Leland Stanford Junior University Stimulation of ovarian follicle development and oocyte maturation
US20130209473A1 (en) * 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
NZ704269A (en) * 2012-07-13 2016-05-27 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
KR20160070136A (ko) 2013-10-18 2016-06-17 제넨테크, 인크. 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2021080396A1 (ko) * 2019-10-24 2021-04-29 가톨릭대학교 산학협력단 Rspo3 억제제를 포함하는 심장 판막 질환의 예방 또는 치료용 조성물
WO2022020544A1 (en) * 2020-07-23 2022-01-27 The Board Of Trustees Of The University Of Illinois Method of treating an inflammatory condition

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO2003094843A2 (en) 2002-05-10 2003-11-20 Incyte Corporation Cell adhesion and extracellular matrix proteins
AU6765098A (en) 1997-03-19 1998-10-12 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
AU7159898A (en) 1997-04-25 1998-11-24 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
GB9828419D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel compounds
AU6117000A (en) 1999-07-26 2001-02-13 Genentech Inc. Novel polynucleotides and method of use thereof
WO2001009316A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Nouveaux genes codant la proteine kinase / proteine phosphatase
US6824973B2 (en) * 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
US6653448B1 (en) 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
WO2001077169A2 (en) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030022255A1 (en) 2000-12-22 2003-01-30 Morris David W. Novel compositions and methods for breast cancer
AU2002253883A1 (en) 2001-01-31 2002-08-12 Incyte Genomics, Inc. Protein modification and maintenance molecules
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US20030032034A1 (en) * 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
EP1383789A2 (en) 2001-04-06 2004-01-28 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
JP4251983B2 (ja) 2001-06-11 2009-04-08 協和発酵キリン株式会社 造血幹細胞または造血前駆細胞の増殖または生存を支持し得るポリペプチドおよびそれをコードするｄｎａ
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
AU2002332454A1 (en) 2001-08-03 2003-04-07 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
EP1427747B1 (en) 2001-08-30 2012-04-11 ARCA biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
CA2483518A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
WO2004080148A2 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2004099408A1 (ja) 2003-05-09 2004-11-18 Research Association For Biotechnology 新規蛋白質およびそれをコードするｄｎａ
US20050054829A1 (en) * 2003-07-22 2005-03-10 Wiley Steven R. Compositions and methods relating to TSP-30a, b, c and d
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
EP1713900A4 (en) 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
WO2007013666A2 (en) * 2005-07-26 2007-02-01 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
WO2007030290A2 (en) 2005-09-07 2007-03-15 Maine Medical Center Research Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto
JP2009511017A (ja) 2005-10-07 2009-03-19 ヌベロ インコーポレーティッド 幹細胞因子様タンパク質ｓｃｆａ１及びその使用
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
CA2664828A1 (en) * 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用

Also Published As

Publication number Publication date
EP2997975A1 (en) 2016-03-23
US8580736B2 (en) 2013-11-12
US10538563B2 (en) 2020-01-21
US20120088727A1 (en) 2012-04-12
PL2081586T5 (pl) 2019-04-30
PL2081586T3 (pl) 2016-07-29
WO2008046649A1 (en) 2008-04-24
JP2014058551A (ja) 2014-04-03
US9226963B2 (en) 2016-01-05
JP2010506871A (ja) 2010-03-04
JP5822897B2 (ja) 2015-11-25
ES2564794T5 (es) 2019-03-14
US10273276B2 (en) 2019-04-30
US8088374B2 (en) 2012-01-03
DK2081586T4 (en) 2019-01-21
EP2081586B1 (en) 2015-12-23
DK2081586T3 (en) 2016-03-14
ES2564794T3 (es) 2016-03-29
AU2007312538B2 (en) 2012-10-04
EP2081586A1 (en) 2009-07-29
HK1222799A1 (zh) 2017-07-14
EP2081586B2 (en) 2018-10-31
US20160009773A1 (en) 2016-01-14
US20140350226A1 (en) 2014-11-27
HUE027179T2 (en) 2016-10-28
US20140056894A1 (en) 2014-02-27
US20190359664A1 (en) 2019-11-28
US20100071078A1 (en) 2010-03-18
JP5777281B2 (ja) 2015-09-09
SI2081586T2 (sl) 2019-01-31
US8926970B2 (en) 2015-01-06
SI2081586T1 (sl) 2016-04-29
AU2007312538A1 (en) 2008-04-24
CA2664828A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
MX2009003726A (es) R-espondinas como moduladores de la angiogenesis y vasculogenesis.
UA104626C2 (ru) Анти-vegf антитело и его применение
DE502007006962D1 (de) Ectoin zur behandlung von vascular leaks
WO2015027259A3 (de) Polypeptid zur hydrolytischen spaltung von zearalenon und/oder zearalenon-derivaten, isoliertes polynukleotid davon sowie einen zusatzstoff enthaltendes polypeptid, verwendung desselben sowie verfahren
MY197720A (en) Bicyclic heterocycles as fgfr inhibitors
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
GB2517875A (en) Modified base detection with nanopore sequencing
MX2016017296A (es) Sintasa del acido cannabicromenico proveniente de cannabis sativa.
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
SG196817A1 (en) Polishing agent for copper polishing and polishing method using same
DE60315355D1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2009011179A (es) Variantes de enzimas asparaginasas y sus usos.
MX343640B (es) Promotor de osteogenesis.
TN2012000042A1 (en) 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhitors
ATE374642T1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
WO2014018601A3 (en) New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
EA201001881A1 (ru) Пролинспецифичная протеаза из penicillium chrysogenum
PH12015500461A1 (en) Novel il-17a binding molecules and medical uses thereof
PL2310043T3 (pl) Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów
UA112024C2 (uk) Цирконієві композиції попередньої обробки, які містять молібден, відповідні способи обробки металевих субстратів та відповідні металеві субстрати з покриттям
MX2018007325A (es) Promotor de catalasa modificado bidireccional de bacilo.
MY161101A (en) Liquid formulations of rupatadine fumarate

Legal Events

Date Code Title Description
FG Grant or registration